**Core Concept:** Long acting insulins are insulin preparations designed to provide a sustained release of insulin over an extended period with minimal fluctuations in plasma concentration. They are crucial for maintaining stable blood glucose levels in diabetic patients.

**Why the Correct Answer is Right:** Glargine (D) is a long-acting insulin analogue developed to mimic the physiological insulin secretion pattern. It is a synthetic insulin that is modified by adding two glutamic acid residues at the B28 and B29 positions, which results in a more stable molecule. Glargine has a slow absorption rate from the subcutaneous tissue, leading to a gradual increase in plasma insulin levels without reaching a peak concentration.

**Why Each Wrong Option is Incorrect:**

A. Insulin Aspart (B) is a rapid-acting insulin analogue that rapidly lowers blood glucose levels but reaches a peak concentration within 1-4 hours post-injection. It is not a long-acting insulin.

B. Insulin Detemir (A) is another long-acting insulin analogue, which is a palmitic acid-modified human insulin. It reaches a peak concentration within 24 hours but is not the correct answer due to its peak concentration.

C. Insulin Glargine (D) is the correct long-acting insulin analogue that does not reach a peak concentration and is suitable for basal insulin therapy in diabetic patients.

**Clinical Pearl:** Adequate insulin therapy in diabetes should aim to mimic the physiological insulin secretion profile. Long-acting insulins, like glargine, should be used as basal insulin in patients with type 1 and type 2 diabetes to maintain a stable glycemic control.

**Correct Answer:** C. Insulin Glargine (D) is a long acting insulin analogue that does not attain a peak concentration in plasma, making it a suitable option for basal insulin therapy in diabetic patients.